Science Corporation, the medical technology startup founded by former Neuralink president Max Hodak in 2021, raised $400 million in Series D funding. The round valued the company at $3.5 billion, according to a person familiar with the deal.

Investors in the round included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.

Science's first product is PRIMA, a wearable and implantable chip that helps people with age-related macular degeneration recover some vision. The device is approved in Europe and available in Germany. The company announced onstage at TechCrunch Disrupt that PRIMA is being trialled for Stargardt's disease, another blindness-causing condition.

Science plans to bring PRIMA to the United States through the FDA's Humanitarian Device Exemption program for rare conditions. The company has convinced the FDA that advanced macular degeneration in both eyes is uncommon enough to pursue U.S. approval.

Beyond PRIMA, Hodak founded Science to leverage new technologies to understand and interact with the brain. The startup is designing initial human trials of a bio-hybrid sensor built from cultured neurons and silicon, working with Yale neurosurgery professor Murat Günel. Günel told TechCrunch the device could offer potential treatments for Parkinson's disease, among other brain injuries and illnesses.